NYSE · ANVS
Healthcare · Biotechnology
$0.96
Down-$0.04 (-4.23%)
Updated Oct 27, 2026, 10:06 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ANVS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
ANVS closed at $0.96 after 21 trading sessions, down 30.65% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $1.00 | $1.00 | $0.9295 | $0.957 | 593.16K |
| Oct 23, 2026 | $0.99 | $1.01 | $0.961 | $0.9993 | 317.23K |
| Oct 22, 2026 | $0.99 | $1.05 | $0.98 | $0.9917 | 448.44K |
| Oct 21, 2026 | $1.00 | $1.04 | $0.9878 | $0.9932 | 546.33K |
| Oct 20, 2026 | $0.96 | $1.04 | $0.96 | $0.9783 | 703.98K |
| Oct 19, 2026 | $0.995 | $1.04 | $0.95 | $0.96 | 641.35K |
| Oct 16, 2026 | $1.06 | $1.08 | $0.987 | $0.9934 | 641.42K |
| Oct 15, 2026 | $1.04 | $1.075 | $1.01 | $1.05 | 572.22K |
| Oct 14, 2026 | $1.05 | $1.08 | $1.01 | $1.02 | 850.26K |
| Oct 13, 2026 | $1.15 | $1.15 | $1.05 | $1.06 | 851.01K |
| Oct 12, 2026 | $1.21 | $1.21 | $1.14 | $1.15 | 460.23K |
| Oct 9, 2026 | $1.17 | $1.24 | $1.14 | $1.21 | 521.9K |
| Oct 8, 2026 | $1.21 | $1.21 | $1.14 | $1.17 | 815.38K |
| Oct 7, 2026 | $1.17 | $1.23 | $1.16 | $1.21 | 430.01K |
| Oct 6, 2026 | $1.20 | $1.24 | $1.17 | $1.18 | 538.72K |
| Oct 5, 2026 | $1.16 | $1.20 | $1.135 | $1.20 | 657.64K |
| Oct 2, 2026 | $1.19 | $1.1964 | $1.135 | $1.18 | 648.54K |
| Oct 1, 2026 | $1.27 | $1.28 | $1.16 | $1.17 | 1.2M |
| Sep 30, 2026 | $1.30 | $1.335 | $1.27 | $1.27 | 572.99K |
| Sep 29, 2026 | $1.39 | $1.41 | $1.30 | $1.30 | 812.05K |
| Sep 28, 2026 | $1.32 | $1.43 | $1.30 | $1.38 | 1.2M |
The latest Smart Investors Daily articles mentioning ANVS.
Company
Market Activity
Research & News
ANVS research
Company profile and research snapshot.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 28, 2026 | Roth Capital | Buy | — |
| Aug 18, 2026 | Canaccord Genuity | Buy | — |
| Jul 8, 2026 | Roth Capital | Buy | — |
| Apr 14, 2026 | Canaccord Genuity | Buy | — |
| Sep 30, 2025 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Finnhub · Apr 13, 2026
MALVERN, Pa. - Annovis Bio, Inc. , a Phase 3 clinical - stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease...
Benzinga · Apr 10, 2026
Financing secures path to first NDA submission for buntanetap6-Month symptomatic data readout anticipated Q1 2027Alzheimer's disease Phase 3 trial 75% enrolledParkinson's disease open-label study 28% enrolledMALVERN,
Fintel · Apr 9, 2026
Benzinga · Apr 9, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ANVS.
